EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes

Jiajie Tu, Weile Chen, Yilong Fang, Dafei Han, Yizhao Chen, Haifeng Jiang, Xuewen Tan, Zhen Xu, Xuming Wu, Huihui Wang, Xiangling Zhu, Wenming Hong und 4 weitere

Annals of the Rheumatic Diseases · 2023-02 · 82 (2) · 198-211

DOI: 10.1136/ard-2022-222708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2023-02. Verfasst von Jiajie Tu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Arthritis, Experimental, Arthritis, Rheumatoid, Synoviocytes, Proto-Oncogene Proteins. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Natural Science Foundation of Anhui Province for young scholars, the Project of Improvement of Scientific Ability of Anhui Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To uncover the function and underlying mechanism of an essential transcriptional factor, PU.1, in the development of rheumatoid arthritis (RA). METHODS: The expression and localisation of PU.1 and its potential target, FMS-like tyrosine kinase 3 (FLT3), in the synovium of patients with RA were determined by western blot and immunohistochemical (IHC) staining. UREΔ (with PU.1 knockdown) and FLT3-ITD (with FLT3 activation) mice were used to establish collagen antibody-induced arthritis (CAIA). For the in vitro study, the effects of PU.1 and FLT3 on primary macrophages and fibroblast-like synoviocytes (FLS) were investigated using siRNAs. Mechanistically, luciferase reporter assays, western blotting, FACS and IHC were conducted to show the direct regulation of PU.1 on the transcription of FLT3 in macrophages and FLS. Finally, a small molecular inhibitor of PU.1, DB2313, was used to further illustrate the therapeutic effects of DB2313 on arthritis using two in vivo models, CAIA and collagen-induced arthritis (CIA). RESULTS: The expression of PU.1 was induced in the synovium of patients with RA when compared with that in osteoarthritis patients and normal controls. FLT3 and p-FLT3 showed opposite expression patterns compared with PU.1 in RA. The CAIA model showed that PU.1 was an activator, whereas FLT3 was a repressor, of the development of arthritis in vivo. Moreover, results from in vitro assays were consistent with the in vivo results: PU.1 promoted hyperactivation and inflammatory status of macrophages and FLS, whereas FLT3 had the opposite effects. In addition, PU.1 inhibited the transcription of FLT3 by directly binding to its promoter region. The PU.1 inhibitor DB2313 clearly alleviated the effects on arthritis development in the CAIA and CIA models. CONCLUSIONS: These results support the role of PU.1 in RA and may have therapeutic implications by directly repressing FLT3. Therefore, targeting PU.1 might be a potential therapeutic approach for RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, ExperimentalArthritis, RheumatoidSynoviocytesProto-Oncogene ProteinsTrans-ActivatorsAnimalsMiceCell ProliferationCells, CulturedFibroblastsfms-Like Tyrosine Kinase 3Synovial MembraneProto-Oncogene Protein Spi-1

Stichwörter der Autor:innen

arthritis, experimentalarthritis, rheumatoidfibroblasts

Substanzen

fms-Like Tyrosine Kinase 3Proto-Oncogene ProteinsTrans-ActivatorsProto-Oncogene Protein Spi-1

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China.
  • College of Pharmacy, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, China.
  • Department of Orthopedics, University of Science and Technology of China, Hefei, Anhui, China.
  • Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China wwei@ahmu.edu.cn.

Förderung

  • The Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China
  • Natural Science Foundation of Anhui Province for young scholars
  • the Project of Improvement of Scientific Ability of Anhui Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Tu, J., Chen, W., Fang, Y., Han, D., Chen, Y., Jiang, H., Tan, X., Xu, Z., Wu, X., Wang, H., Zhu, X., Hong, W., Li, Z., Zhu, C., Wang, X., & Wei, W. (2023). PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes. Annals of the Rheumatic Diseases, 82(2), 198-211. https://doi.org/10.1136/ard-2022-222708

Vancouver

Tu J, Chen W, Fang Y, Han D, Chen Y, Jiang H, et al. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes. Annals of the Rheumatic Diseases. 2023;82(2):198-211. doi:10.1136/ard-2022-222708

BibTeX
@article{Tu2023,
  author = {Tu, Jiajie and Chen, Weile and Fang, Yilong and Han, Dafei and Chen, Yizhao and Jiang, Haifeng and Tan, Xuewen and Xu, Zhen and Wu, Xuming and Wang, Huihui and Zhu, Xiangling and Hong, Wenming and Li, Zhenbao and Zhu, Chen and Wang, Xinming and Wei, Wei},
  title = {PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes},
  journal = {Annals of the Rheumatic Diseases},
  year = {2023},
  volume = {82},
  number = {2},
  pages = {198--211},
  doi = {10.1136/ard-2022-222708}
}
Kostenlos starten →